Who is the CEO of Trevena, Inc.?

Ms. Carrie L. Bourdow is a business executive who currently serves as the CEO of Trevena, Inc..

What is the Revenue Growth of Trevena, Inc.?

Revenue growth data for Trevena, Inc. is currently unavailable.

What is Trevena, Inc. operating Margin?

Trevena, Inc. operating margin is -5869.29% which shows how much profit TRVN earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Trevena, Inc. operate?

Trevena, Inc. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Trevena, Inc. revenue growth?

Revenue growth data for Trevena, Inc. is currently unavailable.

Trevena, Inc.

TRVN•NASDAQ

HealthcareBiotechnology

$1.28

$0.01(0.79%)

Trevena, Inc. (TRVN) Stock Overview

Explore Trevena, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for TRVNStats details for TRVN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for TRVNAnalyst Recommendations details for TRVN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

CEO

Ms. Carrie L. Bourdow

Employees

Headquarters

955 Chesterbrook Boulevard, Chesterbrook, PA

Founded

2014